Cardiovascular Diseases, Congestive Heart Failure, Dilated Cardiomyopathy
Conditions
Keywords
induced pluripotent stem cell, Congestive heart failure, Regenerative medicine, dilated cardiomyopathy
Brief summary
Heart failure is the primary cause of morbidity and mortality worldwide. Currently drug treatments for heart failure manage the symptoms, but not restore the loss cardiomyocytes due to the very limited regenerative capability in the adult heart. Novel reparative therapies that replace the cardiomyocytes loss are highly demanded to restore the cardiac function. The main purposes of this explanatory study is to investigate the safety and efficacy of the catheter-based endocardial delivery of human iPSC-derived cardiomyocytes in patients with congestive heart failure.
Detailed description
Patients with severe congestive heart failure will be treated with allogeneic human iPSC-derived cardiomyocytes (HiCM-188) through the catheter-based injections. HiCM188, produced by Help therapeutics with cGMP condition, will be transplanted into the myocardium through a transcatheter endocardial injection system with two dosage (100 million cells or 400 million cells). The safety and efficacy assessments will be conducted at1, 3, 6 and 12 months after the cell transplantation.
Interventions
BIOLOGICALhiPSC-CM therapy
20 patients with congestive heart failure who met the inclusion and exclusion criteria will be recruited. After being fully informed and signed the informed consent, the patients will be randomly divided into two dosage groups: 100 million cells (10 patients) and 400 million cells (10 patients). Human iPSC-derived cardiomyocytes will be injected into the myocardium through a transcatheter endocardial injection system.
Sponsors
Xijing Hospital
Help Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients aged 18-75 years (including 18 and 75). 2. Signed the informed consent. 3. Patients with congestive heart failure who have received regular treatment for heart failure. 4. New York Heart Association (NYHA) Class III or IV despite optimal standard of care 5. Left Ventricular Ejection Fraction (LVEF)\<40% as assessed by echocardiography ( measure in the 3 months of recruit is included, excluding the measured values within 1 month of myocardial infarction ） 6. The thickness of left ventricular ≥8mm 7. Female patient who is not pregnant or nursing during the clinical trial
Exclusion criteria
1. PRA ≥ 20% or DSA positive. 2. Patients received treatments such as pacemakers, ICD or CRT device. 3. Patient with severe valvular disease or presence of a mechanical valve replacement, such as PCI implantation, or patients requiring simultaneous radiofrequency ablation of atrial fibrillation. 4. Patient with any therapeutic traumatic heart surgery within 30 days. 5. Hemodynamic instability or cardiogenic shock. 6. Right heart failure. 7. Restrictive cardiomyopathy such as amyloidosis, sarcoidosis or hematochromia, constrictive pericarditis. 8. Myocardial infarction occurred within 30 days or stroke occurred within 60 days before enrollment. 9. Thickness at left ventricular free wall infarction \< 6 mm. 10. Severe ventricular arrhythmias (persistent ventricular tachycardia or other conditions that the investigator considers necessary to exclude). 11. Baseline glomerular filtration rate \< 30 ml/min / 1.73 m2. 12. Abnormal liver function: ALT or AST 3 times higher than the normal value. 13. Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cells count \<2,500/ul or platelet count \<100000 / ul. 14. Known allergies to penicillin, streptomycin or radiocontrast agent. 15. Abnormal coagulation function, INR \> 1.3, which cannot be corrected. 16. Contra-indication to performance of a magnetic resonance imaging scan and PET/ECT examinations. 17. Organ transplant recipient 18. Patients with other malignant disease within 5 years prior to enrollment. 19. Non-cardiac condition that limits lifespan to \< 1 year 20. On chronic therapy with immunosuppressant medication such as glucocorticoid or TNFα antagonist 21. Contra-indication to take immunosuppressant medication. 22. Serum positive for infectious diseases (HIV, HBV, HCV, TP). 23. Participated in other clinical trials within the previous 3 months . 24. Female patient who is pregnant or nursing. 25. Other condition that the investigator considers inappropriate for participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of major serious adverse events (SAEs) | First month post-catheterization | Incidence of SAEs is defined as the composite of: death, fatal myocardial infarction, stroke, tamponade, cardiac perforation, ventricular arrhythmias affecting hemodynamics (\> 15s), and tumorigenicity related to the hiPSC-CM . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of newly formed tumors | Baseline, 1,3,6 and 12 months post-catheterization | by comparing chest, abdominal and pelvic CT scan and PET-CT scan |
| Changes in penal reactive antibodies (PRA) | Baseline, 1, 3 and 6 months post-catheterization | Changes in penal reactive antibodies (PRA) as assessed via blooddraw |
| Changes in donor specific antibodies (DSA) | Baseline, 1, 3 and 6 months post-catheterization | Changes in donor specific antibodies (DSA) as assessed via blooddraw |
| Overall Left Ventricular systolic performance as assessed by MRI | Baseline, 1, 3, 6 and 12 months post-catheterization | Left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDV), left ventricular end-systolic dimension (LVESV), evaluated and compared to baseline values. |
| Incidence of severe arrhythmia | 1-6 months post-catheterization | Clinically significant arrhythmias will be recorded by 24-hour ambulatory electrocardiogram |
| Functional status by 6 minute walk test | Baseline, 1,3,6 and 12 months post-catheterization | valuate Functional Capacity via the Six Minute Walk Test |
| Functional status by New York Heart Association (NYHA) Classification | Baseline, 1,3,6 and 12 months post-catheterization | Evaluate Functional Capacity via New York Heart Association (NYHA) Class Determination |
| Minnesota Living With Heart Failure Questionnaire (MLHFQ) | Baseline, 1,3,6 and 12 months post-catheterization | Evaluate Quality Of Life Changes via Minnesota Living with Heart Failure (MLHF). The Maximum possible scores being 105 and the minimum 0. Higher scores indicate a worse or worsening quality of life, while lower scores or decreasing scores indicate a better quality of life. |
| Overall Left Ventricular systolic performance as assessed by PET/ECT Scan | Baseline, 6 and 12 months post-catheterization | Myocardial contraction and relaxation and myocardial perfusion, evaluated and compared to baseline values. |
Countries
China
Contacts
Primary ContactJiaxian Wang, MD, PhD
Outcome results
None listed